{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:37:24Z","timestamp":1788903444074,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00259-025-07185-3","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T04:01:16Z","timestamp":1741406476000},"page":"3114-3124","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Long-term outcomes of Yttrium-90 transarterial radioembolization for patients with hepatocellular carcinoma"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0092-5065","authenticated-orcid":false,"given":"Riccardo","family":"Muglia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"De Giorgio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Saverio","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovico","family":"Dulcetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Prussia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Loglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Ghirardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Antra","family":"Grikke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Luca","family":"Poli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Gerali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola Anna","family":"Erba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Sironi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Fagiuoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Vigan\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,8]]},"reference":[{"key":"7185_CR1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/JHC.S50359","volume":"3","author":"R Sacco","year":"2016","unstructured":"Sacco R, Conte C, Tumino E, Parisi G, Marceglia S, Metrangolo S, et al. Transarterial radioembolization for hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3:25\u20139.","journal-title":"J Hepatocell Carcinoma"},{"key":"7185_CR2","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1097\/01.RVI.0000177063.92678.21","volume":"16","author":"TK Rhee","year":"2005","unstructured":"Rhee TK, Omary RA, Gates V, Mounajjed T, Larson AC, Barakat O, et al. The effect of catheter-directed CT angiography on yttrium-90 radioembolization treatment of hepatocellular carcinoma. J Vasc Interv Radiol. 2005;16:1085\u201391.","journal-title":"J Vasc Interv Radiol"},{"key":"7185_CR3","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1007\/s00259-021-05600-z","volume":"49","author":"M Weber","year":"2022","unstructured":"Weber M, Lam M, Chiesa C, Konijnenberg M, Cremonesi M, Flamen P, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2022;49:1682\u201399.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7185_CR4","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jvir.2023.03.011","volume":"34","author":"GM Knight","year":"2023","unstructured":"Knight GM, Gordon AC, Gates V, Talwar A, Riaz A, Salem R, et al. Evolution of personalized dosimetry for radioembolization of hepatocellular carcinoma. J Vasc Interv Radiol. 2023;34:1214\u201325.","journal-title":"J Vasc Interv Radiol"},{"key":"7185_CR5","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.jvir.2023.02.030","volume":"34","author":"A Villalobos","year":"2023","unstructured":"Villalobos A, Arndt L, Cheng B, Dabbous H, Loya M, Majdalany B, et al. Yttrium-90 radiation segmentectomy of hepatocellular carcinoma: A comparative study of the effectiveness, safety, and dosimetry of Glass-Based versus Resin-Based microspheres. J Vasc Interv Radiol. 2023;34:1226\u201334.","journal-title":"J Vasc Interv Radiol"},{"key":"7185_CR6","doi-asserted-by":"crossref","unstructured":"Mourad SN, De la Garza-Ramos C, Toskich BB. Radiation segmentectomy for the treatment of hepatocellular carcinoma: A practical review of evidence. Cancers (Basel). 2024;16.","DOI":"10.3390\/cancers16030669"},{"key":"7185_CR7","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3390\/curroncol31020045","volume":"31","author":"M Serhal","year":"2024","unstructured":"Serhal M, Dadrass F, Kim E, Lewandowski RJ. Radiation segmentectomy for hepatocellular carcinoma. Curr Oncol. 2024;31:617\u201328.","journal-title":"Curr Oncol"},{"key":"7185_CR8","doi-asserted-by":"crossref","unstructured":"Jeschke M, Ludwig JM, Leyh C, Pabst KM, Weber M, Theysohn JM et al. Bilobar radioembolization carries the risk of radioembolization-Induced liver disease in the treatment of advanced hepatocellular carcinoma: safety and efficacy comparison to systemic therapy with Atezolizumab\/Bevacizumab. Cancers (Basel). 2023;15.","DOI":"10.3390\/cancers15174274"},{"key":"7185_CR9","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, Ferrer-F\u00e0brega J, Burrel M, Garcia-Criado \u00c1, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76:681\u201393.","journal-title":"J Hepatol"},{"key":"7185_CR10","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/hep.31819","volume":"74","author":"R Salem","year":"2021","unstructured":"Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study. Hepatology. 2021;74:2342\u201352.","journal-title":"Hepatology"},{"key":"7185_CR11","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-022-05956-w","volume":"50","author":"R Salem","year":"2023","unstructured":"Salem R, Padia SA, Lam M, Chiesa C, Haste P, Sangro B, et al. Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging. 2023;50:328\u201343.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7185_CR12","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jhep.2017.12.026","volume":"68","author":"C Spreafico","year":"2018","unstructured":"Spreafico C, Sposito C, Vaiani M, Cascella T, Bhoori S, Morosi C, et al. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. J Hepatol. 2018;68:724\u201332.","journal-title":"J Hepatol"},{"key":"7185_CR13","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/hep.26014","volume":"57","author":"V Mazzaferro","year":"2013","unstructured":"Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology. 2013;57:1826\u201337.","journal-title":"Hepatology"},{"key":"7185_CR14","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000489791","volume":"8","author":"R Golfieri","year":"2019","unstructured":"Golfieri R, Bargellini I, Spreafico C, Trevisani F. Patients with Barcelona clinic liver Cancer stages B and C hepatocellular carcinoma: time for a subclassification. Liver Cancer. 2019;8:78\u201391.","journal-title":"Liver Cancer"},{"key":"7185_CR15","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s00270-022-03072-8","volume":"45","author":"B Guiu","year":"2022","unstructured":"Guiu B, Garin E, Allimant C, Edeline J, Salem R. TARE in hepatocellular carcinoma: from the right to the left of BCLC. Cardiovasc Intervent Radiol. 2022;45:1599\u2013607.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"7185_CR16","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1002\/cam4.5125","volume":"12","author":"AM Brown","year":"2023","unstructured":"Brown AM, Kassab I, Massani M, Townsend W, Singal AG, Soydal C, et al. TACE versus TARE for patients with hepatocellular carcinoma: overall and individual patient level meta analysis. Cancer Med. 2023;12:2590\u20139.","journal-title":"Cancer Med"},{"key":"7185_CR17","doi-asserted-by":"crossref","first-page":"e0227711","DOI":"10.1371\/journal.pone.0227711","volume":"15","author":"E Lanza","year":"2020","unstructured":"Lanza E, Muglia R, Bolengo I, Poretti D, D\u2019Antuono F, Ceriani R, et al. Survival analysis of 230 patients with unresectable hepatocellular carcinoma treated with Bland transarterial embolization. PLoS ONE. 2020;15:e0227711.","journal-title":"PLoS ONE"},{"key":"7185_CR18","doi-asserted-by":"crossref","unstructured":"Lopez-Lopez V, Miura K, Kuemmerli C, Capel A, Eshmuminov D, Ferreras D et al. Selecting the appropriate downstaging and bridging therapies for hepatocellular carcinoma: what is the role of transarterial radioembolization? A pooled analysis. Cancers (Basel). 2023;15.","DOI":"10.3390\/cancers15072122"},{"key":"7185_CR19","doi-asserted-by":"crossref","first-page":"100633","DOI":"10.1016\/j.jhepr.2022.100633","volume":"5","author":"F Kolligs","year":"2023","unstructured":"Kolligs F, Arnold D, Golfieri R, Pech M, Peynircioglu B, Pfammatter T, et al. Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: results from the prospective CIRT study. JHEP Rep. 2023;5:100633.","journal-title":"JHEP Rep"},{"key":"7185_CR20","doi-asserted-by":"crossref","first-page":"1346550","DOI":"10.3389\/fradi.2024.1346550","volume":"4","author":"J Wagenpfeil","year":"2024","unstructured":"Wagenpfeil J, Kupczyk PA, Bruners P, Siepmann R, Guendel E, Luetkens JA, et al. Outcome of transarterial radioembolization in patients with hepatocellular carcinoma as a first-line interventional therapy and after a previous transarterial chemoembolization. Front Radio. 2024;4:1346550.","journal-title":"Front Radio"},{"key":"7185_CR21","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2147\/JHC.S248314","volume":"7","author":"A Teyateeti","year":"2020","unstructured":"Teyateeti A, Mahvash A, Long JP, Abdelsalam ME, Avritscher R, Chasen B, et al. Survival outcomes for Yttrium-90 transarterial radioembolization with and without Sorafenib for unresectable hepatocellular carcinoma patients. J Hepatocell Carcinoma. 2020;7:117\u201331.","journal-title":"J Hepatocell Carcinoma"},{"key":"7185_CR22","doi-asserted-by":"crossref","unstructured":"Mosconi C, Cappelli A, Pettinato C, Cocozza MA, Vara G, Terzi E et al. Improved survival after transarterial radioembolisation for hepatocellular carcinoma gives the procedure added value. J Clin Med. 2022;11.","DOI":"10.3390\/jcm11247469"},{"key":"7185_CR23","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182\u2013236.","journal-title":"J Hepatol"},{"key":"7185_CR24","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1007\/s00330-024-10606-w","volume":"34","author":"R Cannella","year":"2024","unstructured":"Cannella R, Zins M, Brancatelli G. ESR essentials: diagnosis of hepatocellular carcinoma-practice recommendations by ESGAR. Eur Radiol. 2024;34:2127\u201339.","journal-title":"Eur Radiol"},{"key":"7185_CR25","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","volume":"76","author":"R de Franchis","year":"2022","unstructured":"de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Baveno VII. Faculty. Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2022;76:959\u201374.","journal-title":"J Hepatol"},{"key":"7185_CR26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/978-3-319-63067-0_12","volume-title":"Clinical applications of nuclear medicine targeted therapy","author":"M Rodari","year":"2018","unstructured":"Rodari M, Muglia R. HCC radioembolization with Yttrium-90 polymer beads (SIR-Spheres). In: Bombardieri E, Seregni E, Evangelista L, Chiesa C, Chiti A, editors. Clinical applications of nuclear medicine targeted therapy. Cham: Springer International Publishing; 2018. pp. 127\u201336."},{"key":"7185_CR27","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jhep.2019.09.026","volume":"72","author":"JM Llovet","year":"2020","unstructured":"Llovet JM, Lencioni R. mRECIST for HCC: performance and novel refinements. J Hepatol. 2020;72:288\u2013306.","journal-title":"J Hepatol"},{"key":"7185_CR28","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/hep.24451","volume":"54","author":"B Sangro","year":"2011","unstructured":"Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology. 2011;54:868\u201378.","journal-title":"Hepatology"},{"key":"7185_CR29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2009.09.006","volume":"138","author":"R Salem","year":"2010","unstructured":"Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138:52\u201364.","journal-title":"Gastroenterology"},{"key":"7185_CR30","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1080\/07357907.2020.1870126","volume":"39","author":"Y Kim","year":"2021","unstructured":"Kim Y, Lee HA, Lee JS, Jeon MY, Kim BK, Park JY, et al. Association between curative treatment after transarterial radioembolization and better survival outcomes in patients with hepatocellular carcinoma. Cancer Invest. 2021;39:274\u201383.","journal-title":"Cancer Invest"},{"key":"7185_CR31","doi-asserted-by":"crossref","unstructured":"Masior \u0141, Krasnod\u0119bski M, Kuncewicz M, Karaban K, Jaszczyszyn I, Kruk E et al. Alpha-Fetoprotein response after first transarterial chemoembolization (TACE) and complete pathologic response in patients with hepatocellular Cancer. Cancers (Basel). 2023;15.","DOI":"10.3390\/cancers15153962"},{"key":"7185_CR32","doi-asserted-by":"crossref","first-page":"e0135298","DOI":"10.1371\/journal.pone.0135298","volume":"10","author":"Y Jeong","year":"2015","unstructured":"Jeong Y, Yoon SM, Han S, Shim JH, Kim KM, Lim Y-S, et al. Propensity score matching analysis of changes in Alpha-Fetoprotein levels after combined radiotherapy and transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor Thrombus. PLoS ONE. 2015;10:e0135298.","journal-title":"PLoS ONE"},{"key":"7185_CR33","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jhep.2011.11.020","volume":"56","author":"K Memon","year":"2012","unstructured":"Memon K, Kulik L, Lewandowski RJ, Wang E, Ryu RK, Riaz A, et al. Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis. J Hepatol. 2012;56:1112\u201320.","journal-title":"J Hepatol"},{"key":"7185_CR34","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1002\/cncr.34754","volume":"129","author":"GK Abou-Alfa","year":"2023","unstructured":"Abou-Alfa GK, Wang X, Parrinello CM, Gossai A, Kim R, Magee K, et al. Association between posttreatment \u03b1-fetoprotein reduction and outcomes in real-world US patients with advanced hepatocellular carcinoma. Cancer. 2023;129:2064\u201374.","journal-title":"Cancer"},{"key":"7185_CR35","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1245\/s10434-009-0788-7","volume":"17","author":"JH Shim","year":"2010","unstructured":"Shim JH, Kim KM, Lee Y-J, Ko G-Y, Yoon H-K, Sung K-B, et al. Complete necrosis after transarterial chemoembolization could predict prolonged survival in patients with recurrent intrahepatic hepatocellular carcinoma after curative resection. Ann Surg Oncol. 2010;17:869\u201377.","journal-title":"Ann Surg Oncol"},{"key":"7185_CR36","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/HEP.0000000000000636","volume":"79","author":"C Campani","year":"2024","unstructured":"Campani C, Vallot A, Ghannouchi H, Allaire M, Evain M, Sultanik P, et al. Impact of radiological response and pattern of progression in patients with HCC treated by atezolizumab-bevacizumab. Hepatology. 2024;79:49\u201360.","journal-title":"Hepatology"},{"key":"7185_CR37","doi-asserted-by":"crossref","first-page":"765","DOI":"10.5009\/gnl19197","volume":"14","author":"JS Lee","year":"2020","unstructured":"Lee JS, Choi HJ, Kim BK, Park JY, Kim DY, Ahn SH, et al. The modified response evaluation criteria in solid tumors (RECIST) yield a more accurate prognoses than the RECIST 1.1 in hepatocellular carcinoma treated with transarterial radioembolization. Gut Liver. 2020;14:765\u201374.","journal-title":"Gut Liver"},{"key":"7185_CR38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13550-022-00879-x","volume":"12","author":"EB Veenstra","year":"2022","unstructured":"Veenstra EB, Ruiter SJS, de Haas RJ, Bokkers RPH, de Jong KP, Noordzij W. Post-treatment three-dimensional voxel-based dosimetry after Yttrium-90 resin microsphere radioembolization in HCC. EJNMMI Res. 2022;12:9.","journal-title":"EJNMMI Res"},{"key":"7185_CR39","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1007\/s00270-018-2008-y","volume":"41","author":"AC Gordon","year":"2018","unstructured":"Gordon AC, Gabr A, Riaz A, Uddin OM, Abouchaleh N, Ali R, et al. Radioembolization super survivors: extended survival in Non-operative hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2018;41:1557\u201365.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"7185_CR40","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/RLU.0000000000002828","volume":"45","author":"M Elsayed","year":"2020","unstructured":"Elsayed M, Ermentrout RM, Sethi I, Bercu ZL, Galt JR, Whitmore M, et al. Incidence of Radioembolization-Induced liver disease and liver toxicity following repeat 90Y-Radioembolization: outcomes at a large tertiary care center. Clin Nucl Med. 2020;45:100\u20134.","journal-title":"Clin Nucl Med"},{"key":"7185_CR41","doi-asserted-by":"crossref","first-page":"20200752","DOI":"10.1259\/bjr.20200752","volume":"94","author":"W Badar","year":"2021","unstructured":"Badar W, Van Ha T, Zangan S, Navuluri R, Pillai A, Baker T, et al. Safety and efficacy of repeat Y90 radioembolization to the same hepatic arterial territory. Br J Radiol. 2021;94:20200752.","journal-title":"Br J Radiol"},{"key":"7185_CR42","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.21037\/atm-20-2658","volume":"8","author":"M Masthoff","year":"2020","unstructured":"Masthoff M, Schindler P, Harders F, Heindel W, Wilms C, Schmidt HH, et al. Repeated radioembolization in advanced liver cancer. Ann Transl Med. 2020;8:1055.","journal-title":"Ann Transl Med"},{"key":"7185_CR43","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1007\/s00270-022-03215-x","volume":"45","author":"E Garin","year":"2022","unstructured":"Garin E, Guiu B, Edeline J, Rolland Y, Palard X. Trans-arterial radioembolization dosimetry in 2022. Cardiovasc Intervent Radiol. 2022;45:1608\u201321.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"7185_CR44","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3348\/kjr.2022.0395","volume":"24","author":"HN Lee","year":"2023","unstructured":"Lee HN, Hyun D. Complications related to transarterial treatment of hepatocellular carcinoma: A comprehensive review. Korean J Radiol. 2023;24:204\u201323.","journal-title":"Korean J Radiol"},{"key":"7185_CR45","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3389\/fonc.2014.00198","volume":"4","author":"A Riaz","year":"2014","unstructured":"Riaz A, Awais R, Salem R. Side effects of yttrium-90 radioembolization. Front Oncol. 2014;4:198.","journal-title":"Front Oncol"},{"key":"7185_CR46","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1007\/s00270-023-03391-4","volume":"46","author":"G Maleux","year":"2023","unstructured":"Maleux G, Albrecht T, Arnold D, Bargellini I, Cianni R, Helmberger T, et al. Predictive factors for adverse event outcomes after transarterial radioembolization with Yttrium-90 resin microspheres in Europe: results from the prospective observational CIRT study. Cardiovasc Intervent Radiol. 2023;46:852\u201367.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"7185_CR47","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1200\/jco.2016.34.4_suppl.217","volume":"34","author":"P Ioannides","year":"2016","unstructured":"Ioannides P, Abuodeh Y, Jin W, Hoffe SE, Frakes JM, Kim RD, et al. Impact of sarcopenia evaluated using the total Psoas area (TPA) in patients undergoing Y-90 radioembolization for hepatocellular carcinoma (HCC). J Clin Oncol. 2016;34:217\u2013217.","journal-title":"J Clin Oncol"},{"key":"7185_CR48","doi-asserted-by":"crossref","first-page":"e0232371","DOI":"10.1371\/journal.pone.0232371","volume":"15","author":"E Lanza","year":"2020","unstructured":"Lanza E, Masetti C, Messana G, Muglia R, Pugliese N, Ceriani R, et al. Sarcopenia as a predictor of survival in patients undergoing Bland transarterial embolization for unresectable hepatocellular carcinoma. PLoS ONE. 2020;15:e0232371.","journal-title":"PLoS ONE"},{"key":"7185_CR49","doi-asserted-by":"crossref","first-page":"e0198812","DOI":"10.1371\/journal.pone.0198812","volume":"13","author":"H Takada","year":"2018","unstructured":"Takada H, Kurosaki M, Nakanishi H, Takahashi Y, Itakura J, Tsuchiya K, et al. Impact of pre-sarcopenia in Sorafenib treatment for advanced hepatocellular carcinoma. PLoS ONE. 2018;13:e0198812.","journal-title":"PLoS ONE"},{"key":"7185_CR50","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/hepr.12562","volume":"46","author":"S Kamachi","year":"2016","unstructured":"Kamachi S, Mizuta T, Otsuka T, Nakashita S, Ide Y, Miyoshi A, et al. Sarcopenia is a risk factor for the recurrence of hepatocellular carcinoma after curative treatment. Hepatol Res. 2016;46:201\u20138.","journal-title":"Hepatol Res"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07185-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07185-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07185-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T01:52:27Z","timestamp":1751421147000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07185-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,8]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["7185"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07185-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,8]]},"assertion":[{"value":"16 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective, single-center study was conducted in accordance with the Declaration of Helsinki and approved by the local ethics committee (protocol no. 132\u2009\u2212\u200921).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent for anonymous data collection and study participation was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Informed consent for anonymous data publication was obtained from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Prof. Paola Anna Erba declares a conflict of interest on the publication of this manuscript on European Journal of Nuclear Medicine and Molecular Imaging, being part of its Editorial Board. All the other Authors declare no conflict of interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}